|
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion.
DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- GenScript announced the official opening of its first European mRNA production site in Delft, the Netherlands, marking a significant expansion of the company's global mRNA platform and reinforcing Europe as a core pillar of its integrated R&D and production network.
The Delft facility strengthens GenScript's transatlantic biotechnology infrastructure, enabling greater regional proximity, regulatory alignment, and supply chain resilience for European innovators developing next-generation therapies, vaccines, and advanced biologics.
"Having a local GenScript facility in the EU makes a real difference for us," said Paula Río, PhD, Hematopoietic Innovative Therapies Unit, CIEMAT/CIBERER/FJD, UAM. "The closer proximity enables more seamless collaboration, faster turnaround times, and reduced shipping delays. Working with a team that's fully aligned with EU regulations and standards strengthens the partnership and makes day‑to‑day interactions significantly easier."
This ability to translate global capabilities into regionally embedded, customer‑ready infrastructure reflects GenScript's broader platform strategy. As a U.S.-founded biotechnology company established in New Jersey more than two decades ago, GenScript continues to expand its innovation footprint across North America and Europe through disciplined, long-term investment in scalable platform infrastructure.
"Europe is not an outpost in our network; it is a core pillar of our global mRNA platform," said Shawn Wu, President of GenScript EU Division. "By integrating Delft into our unified global operating system, we are delivering greater speed, regulatory alignment, and operational resilience for our partners, while maintaining one uncompromising global standard."
A Platform Expansion; Not a Standalone Facility
Built within one of Europe's strongest life science ecosystems, the Delft site provides end-to-end mRNA workflow capabilities, including:
- Gene design and synthesis
- Vector engineering
- IVT mRNA production
- Proprietary GenCap™ mRNA capping technology
- UTR optimization and formulation support
The facility operates within GenScript's AI-enabled digital operating model, supporting process consistency, accelerated turnaround times, and seamless integration with the company's global R&D and manufacturing network.
By aligning with EU regulatory standards while remaining fully integrated into GenScript's global quality systems, the site enables customers to move efficiently from research-grade mRNA to downstream development pathways across regions.
Integrated Global Continuity
The Delft opening follows GenScript's continued expansion of its U.S. innovation footprint, including capacity growth at its New Jersey campus, and complements its broader global operations across North America, Europe, and Asia.
Together, these investments reflect GenScript's coordinated strategy to build resilient, high-quality growth platforms that support life science innovation from early discovery through advanced development stages.
The company's mRNA capabilities are part of a broader integrated biotechnology ecosystem from discovery to development to manufacturing; enabling to move from idea to impact within a unified global system.
Supporting Europe's Innovation Momentum
GenScript established its European Division headquarters in the Netherlands in 2021 and has steadily expanded regional operations since then. The Delft mRNA site deepens that commitment by strengthening local access to advanced mRNA technologies while maintaining global scale.
"From our first conversations, GenScript has demonstrated a strong commitment to innovation, collaboration, and scientific excellence," said Cindy Gerhardt, Managing Director of Planet B.io. "We've built a valuable partnership driven by a shared ambition to accelerate biotech research and innovation. The opening of this state-of-the-art lab strengthens the position of the Biotech Campus Delft—not only for our own community, but for the broader European biotech ecosystem."
"This expansion reflects disciplined execution of our global platform strategy," said Sherry Shao, CEO of GenScript Biotech Corporation. "As a U.S.-founded company committed to advancing biotechnology worldwide, we continue to invest in resilient, regionally anchored infrastructure that supports innovation with speed, quality, and trust. At GenScript, 'Scripting Possibilities' means building the integrated global systems that allow science to move confidently from discovery to development, across regions, and at scale."
Advancing the Future of mRNA Innovation
The Delft expansion represents one chapter in GenScript's long-term strategy to build scalable, automation-driven biotechnology platforms worldwide; advancing scientific discovery through integrated, high-quality infrastructure designed for the future of therapeutic development.
About GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 5,500+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies.
Media Contact:
Melis Inceer, Head of Integrated Communications & Content
Melis.Inceer@genscript.com
+1 (628) 224-3831
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion.
DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- GenScript announced the official opening of its first European mRNA production site in Delft, the Netherlands, marking a significant expansion of the company's global mRNA platform and reinforcing Europe as a core pillar of its integrated R&D and production network.
The Delft facility strengthens GenScript's transatlantic biotechnology infrastructure, enabling greater regional proximity, regulatory alignment, and supply chain resilience for European innovators developing next-generation therapies, vaccines, and advanced biologics.
"Having a local GenScript facility in the EU makes a real difference for us," said Paula Río, PhD, Hematopoietic Innovative Therapies Unit, CIEMAT/CIBERER/FJD, UAM. "The closer proximity enables more seamless collaboration, faster turnaround times, and reduced shipping delays. Working with a team that's fully aligned with EU regulations and standards strengthens the partnership and makes day‑to‑day interactions significantly easier."
This ability to translate global capabilities into regionally embedded, customer‑ready infrastructure reflects GenScript's broader platform strategy. As a U.S.-founded biotechnology company established in New Jersey more than two decades ago, GenScript continues to expand its innovation footprint across North America and Europe through disciplined, long-term investment in scalable platform infrastructure.
"Europe is not an outpost in our network; it is a core pillar of our global mRNA platform," said Shawn Wu, President of GenScript EU Division. "By integrating Delft into our unified global operating system, we are delivering greater speed, regulatory alignment, and operational resilience for our partners, while maintaining one uncompromising global standard."
A Platform Expansion; Not a Standalone Facility
Built within one of Europe's strongest life science ecosystems, the Delft site provides end-to-end mRNA workflow capabilities, including:
- Gene design and synthesis
- Vector engineering
- IVT mRNA production
- Proprietary GenCap™ mRNA capping technology
- UTR optimization and formulation support
The facility operates within GenScript's AI-enabled digital operating model, supporting process consistency, accelerated turnaround times, and seamless integration with the company's global R&D and manufacturing network.
By aligning with EU regulatory standards while remaining fully integrated into GenScript's global quality systems, the site enables customers to move efficiently from research-grade mRNA to downstream development pathways across regions.
Integrated Global Continuity
The Delft opening follows GenScript's continued expansion of its U.S. innovation footprint, including capacity growth at its New Jersey campus, and complements its broader global operations across North America, Europe, and Asia.
Together, these investments reflect GenScript's coordinated strategy to build resilient, high-quality growth platforms that support life science innovation from early discovery through advanced development stages.
The company's mRNA capabilities are part of a broader integrated biotechnology ecosystem from discovery to development to manufacturing; enabling to move from idea to impact within a unified global system.
Supporting Europe's Innovation Momentum
GenScript established its European Division headquarters in the Netherlands in 2021 and has steadily expanded regional operations since then. The Delft mRNA site deepens that commitment by strengthening local access to advanced mRNA technologies while maintaining global scale.
"From our first conversations, GenScript has demonstrated a strong commitment to innovation, collaboration, and scientific excellence," said Cindy Gerhardt, Managing Director of Planet B.io. "We've built a valuable partnership driven by a shared ambition to accelerate biotech research and innovation. The opening of this state-of-the-art lab strengthens the position of the Biotech Campus Delft—not only for our own community, but for the broader European biotech ecosystem."
"This expansion reflects disciplined execution of our global platform strategy," said Sherry Shao, CEO of GenScript Biotech Corporation. "As a U.S.-founded company committed to advancing biotechnology worldwide, we continue to invest in resilient, regionally anchored infrastructure that supports innovation with speed, quality, and trust. At GenScript, 'Scripting Possibilities' means building the integrated global systems that allow science to move confidently from discovery to development, across regions, and at scale."
Advancing the Future of mRNA Innovation
The Delft expansion represents one chapter in GenScript's long-term strategy to build scalable, automation-driven biotechnology platforms worldwide; advancing scientific discovery through integrated, high-quality infrastructure designed for the future of therapeutic development.
About GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 5,500+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies.
Media Contact:
Melis Inceer, Head of Integrated Communications & Content
Melis.Inceer@genscript.com
+1 (628) 224-3831
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
Technology Reaches International Advanced Level, Accelerating Global Market Expansion
QINGDAO, China, March 12, 2026 /PRNewswire/ -- A news report from iQingdao: Recently, the "Low-Carbon Industrialized Complete Technology and Equipment for Functional Nanofiber Nonwoven Materials" independently developed by Surforce (Qingdao) Technology Group Co., Ltd. (hereinafter referred to as "Surforce Technology Group") has passed authoritative appraisal, with the overall technology reaching internationally advanced levels. This breakthrough not only resolves the worldwide challenge of electrospinning industrialization but also provides the global market with a fluorine-free, environmentally friendly PTFE alternative solution, leveraging the cost advantages brought by mass production.
Since its establishment in 2003, Surforce Technology Group has remained dedicated to the R&D and industrial application of advanced materials. Through years of technological accumulation, the company has built China's first ten-million-meter-scale nanofiber factory, with an annual production capacity of 20 to 30 million meters.
In 2025, the Group received high-level national and industry recognition in this field: Won Second Prize for Scientific and Technological Progress from the China National Textile and Apparel Council; Awarded the "Top Ten Textile Technologies in China" achievement title; Selected for the Ministry of Industry and Information Technology's 2025 Key Products and Processes "End-to-End" Application Plan and the Qingdao Municipal Science and Technology Bureau's Key Technology Research Projects.
The Group's core product, "Surforce Nanofiber Membrane," features extremely large specific surface area, excellent mechanical properties, composite structural performance, and special physical and chemical characteristics. It can be produced using various raw materials and is widely applied in new energy, high-end filtration, consumer electronics, and textile sectors. The product serves as a separator material for semi-solid-state batteries, high-end filtration (high-temperature gas dust collection) material, and waterproof breathable material for consumer electronics. In the textile field, this product overcomes the limitations of traditional PTFE and TPU membranes in terms of breathability and elasticity, driving the extension of protective clothing into daily functional apparel. The company has already established partnerships with renowned domestic and international brands.
The Group places strong emphasis on R&D investment and intellectual property system development. It currently holds 25 authorized patents at home and abroad, has passed TÜV Rheinland certification, and obtained internationally authoritative certifications including ISO 9001, OEKO-TEX, and GRS.
In response to global opportunities in the new materials industry, the Group will continue to deepen its full-chain innovation system and promote the large-scale application of high-performance nanofiber materials. "We will remain technology-driven, committed to bringing Chinese nanomaterials to the world and providing global customers with cost-effective, environmentally friendly solutions," said a senior executive of Surforce Technology Group.
About Surforce Technology Group:
Established in 2003, Surforce Technology Group is a leading Chinese manufacturer of functional nanomaterials, possessing a complete independent intellectual property system. The company is committed to providing global customers with high-performance, low-carbon, and environmentally friendly nanomaterial solutions.
Contact us:
https://www.surforce.cc/
eos@lerune.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Surforce Technology Group Achieves Major Breakthrough in Functional Nanofiber Nonwoven Materials
![[MWC 2026] GSMA Releases Experience Specifications for AI Calling Native Applications](https://image.bastillepost.com/704x369/wp-content/uploads/global/2026/03/media2_2932316_image1_FB.jpg.webp)
